期刊文献+

肝癌患者PD-1、PD-L1、CMTM6水平与术后复发风险的相关性

The correlation between the levels of PD-1,PD-L1,and CMTM6 in patients with liver cancer and the risk of postoperative recurrence
下载PDF
导出
摘要 目的探讨肝癌患者程序性死亡受体1(PD-1)、程序性死亡配体(PD-L1)、趋化素样因子超家族6(CMTM6)水平与术后复发风险的相关性。方法前瞻性选取2017年6月~2018年6月我院肝癌术后患者102例,随访观察3年,采用Kaplan-Meier绘制复发曲线,并根据复发情况分为复发组和非复发组。收集两组一般资料、肿瘤因素、肝脏功能状态、健康状态及免疫水平(PD-1、PD-L1、CMTM6免疫组织化学染色情况),并采用Logistic回归分析影响肝癌患者术后复发的相关因素。结果随访结束,共3例因各种原因失访,最终纳入99例,Kaplan-Meier曲线累积复发率为35.35%,复发时间(25.80±3.20)月,其中复发组35例非复发组64例;两组肿瘤直径、BCLC分期、PD-L1、PD-1、CMTM6对比差异具有统计学意义(P<0.05);多因素Logistic回归分析显示:PD-1(0R=3.632,95%CI1.393~9.470)、CMTM6(OR=2.496,95%CI1.274~4.890)、肿瘤直径(0R=3.015,95%CI1.039~8.753)、PD-L1(0R=2.803,95%CI1.335~5.885)为肝癌术后复发的危险因素(均P<0.05)。结论PD-1、PD-L1、CMTM6水平在肝癌术后复发过程中发挥着重要作用,这可能成为肝癌治疗的一个新方向。 Objective To explore the correlation between the levels of programmed death receptor 1(PD-1),programmed death ligand(PD-L1),chemokine-like factor superfamily 6(CMTM6)and the risk of postoperative recurrence in patients with liver cancer.Methods Prospectively selected 102 patients after liver cancer surgery in our hospital from June 2017 to June 2018.Followed up for 3 years,Kaplan-Meier was used to draw the recurrence curve,and the recurrence was divided into recurrence group and non-recurrence group.Collected two groups of general information,tumor factors,liver function status,health status and immune level(PD-1,PD-L1,CMTM6 immunohistochemical staining),Used Logistic regression to analyze the related factors that affect the recurrence of liver cancer patients after surgery.ResultsAt the end of the follow-up,a total of 3 cases were lost to follow-up due to various reasons,and 99 cases were finally included.The cumulative recurrence rate of Kaplan-Meier curve was 35.35%,and the recurrence time was(25.80±3.20)months,including 35 cases in the recurrence group and 64 cases in the non-recurrence group;The difference in tumor diameter,BCLC staging,PD-L1,PD-1,CMTM6 between the two groups was statistically significant(P<0.05);Multivariate logistic regression analysis showed:PD-1(OR=3.632,95%CI1.393~9.470,CMTM6(0R=2.496,95%CI1.274~4.890),tumor diameter(OR=3.015,95%CI1.039~8.753),PD-L1(OR=2.803,95%CI1.335~5.885)were risk factors for recurrence of liver cancer after surgery(all P<0.05).Conclusion The levels of PD-1,PD-L1,and CMTM6 play an important role in the recurrence of liver cancer after surgery,which may become a new direction in the treatment of liver cancer.
作者 彭启旺 邓浩 刘小卫 PEN Qi-wang;DEN Hao;LIU Xiao-wei(The Red Cross Hospital of Wnhan,Wuhan 430021,China)
出处 《肝胆外科杂志》 2023年第3期209-213,共5页 Journal of Hepatobiliary Surgery
关键词 程序性死亡受体1 肝癌 程序性死亡配体 趋化素样因子超家族6 手术 肿瘤复发 programmed death receptor 1 liver cancer programmed death ligand chemokine-like factor superfamily 6 operation tumorrecurrence
  • 相关文献

参考文献2

二级参考文献57

  • 1吴孟超.应重视小肝癌的诊断与治疗[J].中华医学杂志,2007,87(30):2089-2091. 被引量:11
  • 2Koh C, Zhao X, Samala N, et al. AASLD clinical practice guide- lines: a critical review of scientific evidence and evolving reco- mmendations[J]. Hepatology, 2013, 58(6): 2142-2152.
  • 3William H, Ralph H, Timothy H, et al. Surgical pathology dissec- tion: an illustrated guide[ M]. New York:Springer, 2003:7-9.
  • 4Bass BP, Engel KB, Greytak SR, et al. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin- embedded ( FFPE ) tissue : how well do you know your FFPE specimen? [ J]. Arch Pathol Lab Med, 2014, 138(11): 1520-1530.
  • 5Lu XY, Xi T, Lau WY, et al. Hepatoeellular carcinoma expres- sing cholangiocyte phenotype is a novel subtype with highly aggressive behavior [ J ]. Ann Surg Oncol, 2011, 18 ( 8 ) : 2210-2217.
  • 6Cai SW, Yang SZ, Gao J, et al. Prognostic significance of mast cell count following curative resection for pancreatic ductal adeno- carcinoma[ J ]. Surgery, 201 l, 149 (4) : 576-584.
  • 7应越英.肝细胞肝癌的病理学//汤钊猷,主编.原发性肝癌[M].上海:上海科学技术出版社,1981:115-146.
  • 8Nakanuma Y, Curado MP, Franceschi S, et al. Intrahepatic cholangiocarcinoma//Bosman FT, Carneiro F, Hruban RH, et al, eds. WHO Classification of Tumours of the Digestive System[M]. 4th ed. Lyon:IARC Press, 2010: 217-227.
  • 9Cong WM, Wu MC. Small hepatocellular carcinoma: current and future approaches[J]. Hepatol Int, 2013, 7(3) : 805-812.
  • 10Lu XY, Xi T, Lau WY, et al. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and bio- logical behavior[J]. J Cancer Res Clin Oncol, 2011, 137 (4): 567-575.

共引文献437

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部